{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T12:35:09Z","timestamp":1718800509924},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Shanghai Municipal Health Commission Scientific Research Project","award":["201940225"],"award-info":[{"award-number":["201940225"]}]},{"name":"Shanghai major projects on infectious diseases","award":["shslczdzk01102"],"award-info":[{"award-number":["shslczdzk01102"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"DOI":"10.1007\/s12185-021-03101-1","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T02:34:53Z","timestamp":1613702093000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world outcomes of AIDS-related Burkitt lymphoma: a retrospective study of 78 cases over a 10-year period"],"prefix":"10.1007","author":[{"given":"Zhenyan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangyun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinzhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tangkai","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuibao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhou","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"3101_CR1","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","volume":"4","author":"RU Hern\u00e1ndez-Ram\u00edrez","year":"2017","unstructured":"Hern\u00e1ndez-Ram\u00edrez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017;4:e495\u2013504.","journal-title":"Lancet HIV"},{"key":"3101_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13027-017-0120-2","volume":"12","author":"Y Shen","year":"2017","unstructured":"Shen Y, Zhang R, Liu L, Shen Y, Song W, Qi T, et al. Clinical and prognostic analysis of 78 patients with human immuno-deficiency virus associated non-Hodgkin\u2019s lymphoma in Chinese population. Infect Agent Cancer. 2017;12:7.","journal-title":"Infect Agent Cancer"},{"key":"3101_CR3","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1038\/s41598-019-41869-9","volume":"9","author":"D Wu","year":"2019","unstructured":"Wu D, Chen C, Zhang M, Li Z, Wang S, Shi J, et al. The clinical features and prognosis of 100 AIDS-related lymphoma cases. Sci Rep. 2019;9:5381.","journal-title":"Sci Rep"},{"key":"3101_CR4","unstructured":"B-cell lymphomas, version 1.2020. NCCN Clinical Practice Guidelines in Oncology."},{"key":"3101_CR5","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"3101_CR6","unstructured":"Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at: http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adult_oi.pdf. Accessed 1 Oct 2020."},{"key":"3101_CR7","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"3101_CR8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006926","author":"AM Evens","year":"2020","unstructured":"Evens AM, Danilov AV, Jagadeesh D, Sperling AL, Kim SH, Vaca RA, et al. Burkitt lymphoma in the modern era: real world outcomes and prognostication across 30 US cancer centers. Blood. 2020. https:\/\/doi.org\/10.1182\/blood.2020006926 (in press).","journal-title":"Blood"},{"key":"3101_CR9","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.3324\/haematol.2013.086827","volume":"98","author":"T Intermesoli","year":"2013","unstructured":"Intermesoli T, Rambaldi A, Rossi G, Delaini F, Romani C, Pogliani EM, et al. High cure rates in Burkitt lymphoma and leukemia: a Northern Italy leukemia group study of the German short intensive rituximab-chemotherapy program. Haematologica. 2013;98:1718\u201325.","journal-title":"Haematologica"},{"key":"3101_CR10","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.3109\/10428194.2013.878933","volume":"55","author":"B Xicoy","year":"2014","unstructured":"Xicoy B, Ribera JM, M\u00fcller M, Garc\u00eda O, Hoffmann C, Oriol A, et al. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma\/leukemia: parallel study of 81 patients. Leuk Lymphoma. 2014;55:2341\u20138.","journal-title":"Leuk Lymphoma"},{"key":"3101_CR11","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/bjh.13221","volume":"168","author":"P Schommers","year":"2015","unstructured":"Schommers P, Hentrich M, Hoffmann C, Gillor D, Zoufaly A, Jensen B, et al. Survival of AIDS-related diffuse large B cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV lymphoma cohort. Br J Haematol. 2015;168:806\u201310.","journal-title":"Br J Haematol"},{"key":"3101_CR12","doi-asserted-by":"publisher","first-page":"106287","DOI":"10.1016\/j.leukres.2019.106287","volume":"89","author":"WFD Silva","year":"2020","unstructured":"Silva WFD, Garibaldi PMM, Rosa LID, Bellesso M, Cl\u00e9 DV, Delamain MT, et al. Outcomes of HIV-associated Burkitt lymphoma in Brazil: high treatment toxicity and refractoriness rates\u2014a multicenter cohort study. Leuk Res. 2020;89:106287.","journal-title":"Leuk Res"},{"key":"3101_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1158\/1055-9965.EPI-16-0595","volume":"26","author":"X Han","year":"2017","unstructured":"Han X, Jemal A, Hulland E, Simard EP, Nastoupil L, Ward E, et al. HIV infection and survival of lymphoma patients in the era of highly active antiretroviral therapy. Cancer Epidemiol Biomarker Prev. 2017;26:303\u201311.","journal-title":"Cancer Epidemiol Biomarker Prev"},{"key":"3101_CR14","doi-asserted-by":"publisher","first-page":"904201","DOI":"10.1155\/2013\/904201","volume":"2013","author":"E Luz","year":"2013","unstructured":"Luz E, Marques M, Luz I, Stelitano C, Netto E, Ara\u00fajo I, et al. Survival and prognostic factors for AIDS and non-AIDS patients with non-Hodgkin\u2019s lymphoma in Bahia, Brazil: a retrospective cohort study. ISRN Hematol. 2013;2013:904201.","journal-title":"ISRN Hematol."},{"key":"3101_CR15","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3324\/haematol.2014.111112","volume":"99","author":"SK Barta","year":"2014","unstructured":"Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, et al. A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica. 2014;99:1731\u20137.","journal-title":"Haematologica"},{"key":"3101_CR16","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1182\/blood.2019001880","volume":"134","author":"RI Panea","year":"2019","unstructured":"Panea RI, Love CL, Shingleton JR, Reddy A, Bailey JA, Moormann AM, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134:1598\u2013607.","journal-title":"Blood"},{"key":"3101_CR17","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","volume":"369","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt\u2019s lymphoma. N Engl J Med. 2013;369:1915\u201325.","journal-title":"N Engl J Med"},{"key":"3101_CR18","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1200\/JCO.20.00303","volume":"38","author":"M Roschewski","year":"2020","unstructured":"Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt Lymphoma. J Clin Oncol. 2020;38:2519\u201329.","journal-title":"J Clin Oncol"},{"key":"3101_CR19","doi-asserted-by":"publisher","first-page":"735392","DOI":"10.1155\/2012\/735392","volume":"2012","author":"JA Rodrigo","year":"2012","unstructured":"Rodrigo JA, Hicks LK, Cheung MC, Song KW, Ezzat H, Leger CS, et al. HIV-associated Burkitt lymphoma: good efficacy and tolerance of intensive chemotherapy including CODOX-M\/IVAC with or without rituximab in the HAART era. Adv Hematol. 2012;2012:735392.","journal-title":"Adv Hematol."},{"key":"3101_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","volume":"126","author":"A Noy","year":"2015","unstructured":"Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, et al. AMC 048: modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015;126:160\u20136.","journal-title":"Blood"},{"key":"3101_CR21","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1097\/QAD.0000000000000623","volume":"29","author":"F Alwan","year":"2015","unstructured":"Alwan F, He A, Montoto S, Kassam S, Mee M, Burns F, et al. Adding rituximab to CODOX-M\/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy. AIDS. 2015;29:903\u201310.","journal-title":"AIDS"},{"key":"3101_CR22","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","volume":"387","author":"V Ribrag","year":"2016","unstructured":"Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt\u2019s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:2402\u201311.","journal-title":"Lancet"},{"key":"3101_CR23","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","volume":"122","author":"SK Barta","year":"2013","unstructured":"Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122:3251\u201362.","journal-title":"Blood"},{"key":"3101_CR24","doi-asserted-by":"publisher","first-page":"986","DOI":"10.6004\/jnccn.2018.0066","volume":"16","author":"E Reid","year":"2018","unstructured":"Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, et al. Cancer in people living with HIV, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:986\u20131017.","journal-title":"J Natl Compr Canc Netw"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03101-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-021-03101-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03101-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T02:37:13Z","timestamp":1613702233000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-021-03101-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":24,"alternative-id":["3101"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03101-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"30 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}